Nordicus Partners Corporation (NORD)
OTCMKTS
· Delayed Price · Currency is USD
4.500
0.00 (0.00%)
Feb 19, 2025, 4:00 PM EST
Nordicus Partners Revenue
Nordicus Partners had revenue of $2.50K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $5.00K. In the fiscal year ending March 31, 2024, Nordicus Partners had annual revenue of $2.50K.
Revenue (ttm)
5.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
77.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 2.50K | - | - |
Mar 31, 2023 | - | - | - |
Mar 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNordicus Partners News
- 4 days ago - Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study - GlobeNewsWire
- 19 days ago - Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia - GlobeNewsWire
- 25 days ago - Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment - GlobeNewsWire
- 5 weeks ago - Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin's Breakthrough Treatment for Periodontitis - GlobeNewsWire
- 2 months ago - Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025 - GlobeNewsWire
- 2 months ago - NORDICUS now trading under symbol NORD - GlobeNewsWire
- 3 months ago - Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S - GlobeNewsWire
- 3 months ago - Nordicus Partners Corporation Acquires Bio-Convert ApS - GlobeNewsWire